07:00 , Apr 7, 2014 |  BC Week In Review  |  Financial News

Hybrigenics completes private placement

Hybrigenics S.A. (Euronext: ALHYG), Paris, France   Business: Cancer, Proteomics, Supply/Service   Date completed: 3/26/14   Type: Private placement   Raised: €3.8 million ($5.2 million)   Shares: 1.6 million   Price: €2.35   Shares after...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Financial News

Hybrigenics completes private placement

Hybrigenics S.A. (Euronext: ALHYG), Paris, France   Business: Cancer, Proteomics, Supply/Service   Date completed: 3/26/14   Type: Private placement   Raised: €2.3 million ($3.2 million)   Shares: 932,730   Price: €2.50   Shares after offering:...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Financial News

Nanobiotix completes IPO

Nanobiotix S.A. , Paris, France   Business: Drug delivery, Cancer   Date completed: 10/24/12   Type: IPO   Raised: €14.3 million ($18.5 million)   Shares: 2.4 million   Price: €6   Shares after offering: 10.7...
00:29 , Oct 25, 2012 |  BC Extra  |  Financial News

Nanobiotix raises EUR 14.2M in French IPO

Nanobiotix S.A. (Paris, France) raised EUR 14.2 million ($18.5 million) through the sale of 2.4 million shares at EUR 6 in an IPO on NYSE Euronext Paris. The EUR 6 price values the company at...
00:30 , Oct 12, 2012 |  BC Extra  |  Financial News

Nanobiotix sets IPO range

Nanobiotix S.A. (Paris, France) set the proposed price range and number of shares for its IPO on NYSE Euronext Paris at up to 2.1 million shares and EUR 5.04-EUR 6.16. At the EUR 5.60 midpoint,...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Company News

sanofi-aventis sales and marketing update

sanofi-aventis launched its Allegra fexofenadine products in the U.S. for OTC use in adults and children 2 years or older to treat symptoms associated with seasonal allergic rhinitis. FDA approved the Allegra family of antihistamines,...
08:00 , Jan 31, 2011 |  BC Week In Review  |  Clinical News

Allegra fexofenadine regulatory update

FDA approved Allegra fexofenadine products from sanofi-aventis for OTC use in adults and children >=2 years old to treat symptoms associated with seasonal allergic rhinitis. The Allegra family of antihistamines, which includes Allegra, Allegra-D 12...
07:00 , Sep 6, 2010 |  BioCentury  |  Strategy

Laying siege

sanofi-aventis Group made clear in its conference call last week that it's in no hurry to complete its proposed acquisition of Genzyme Corp. - with the obvious implication that time is on its side. If...
07:00 , Jun 22, 2009 |  BioCentury  |  Regulation

Crystalizing a Place for Krystexxa

Assuming FDA concurs with last week's positive advisory panel vote for Krystexxa pegloticase to treat refractory chronic gout, the next big task for Savient Pharmaceuticals Inc. is likely to be positioning Krystexxa in a market...
08:00 , Mar 3, 2008 |  BC Week In Review  |  Company News

Sciele, sanofi-aventis sales and marketing update

Sciele received exclusive rights to market sanofi-aventis' allergic rhinitis therapeutics Allegra fexofenadine orally disintegrating tablets (ODT) and Allegra oral suspension in the U.S. Under the three-year deal, Sciele is responsible for sales and marketing, and...